PUMA BIOTECHNOLOGY, INC. Costs and Expenses
PUMA BIOTECHNOLOGY, INC. (PBYI) reported Costs and Expenses of $48.92 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2026-08-06
- PUMA BIOTECHNOLOGY, INC. costs and expenses for the quarter ending 2026-06-30 was $48.92M, a 6.81% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. costs and expenses for the quarter ending 2026-03-31 was $48.64M, a 15.75% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. costs and expenses for the quarter ending 2025-12-31 was $58.35M, a 27.64% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. costs and expenses for the quarter ending 2025-09-30 was $44.90M, a 23.20% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. costs and expenses for fiscal 2025 was $191.07M, a 4.23% decline from fiscal 2024.
- PUMA BIOTECHNOLOGY, INC. costs and expenses for fiscal 2024 was $199.50M, a 1.72% decline from fiscal 2023.
- PUMA BIOTECHNOLOGY, INC. costs and expenses for fiscal 2023 was $203.00M, a 0.64% decline from fiscal 2022.
- PUMA BIOTECHNOLOGY, INC. costs and expenses for fiscal 2022 was $204.31M, a 18.88% decline from fiscal 2021.
| Period end | Costs and Expenses 3 month | Costs and Expenses 6 month | Costs and Expenses 9 month | Costs and Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $48.92M 10-Q · filed 2026-08-06 | $97.56M 10-Q · filed 2026-08-06 | $155.91M derived: sum of 3 quarters · filed 2026-08-06 | $200.81M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $48.64M 10-Q · filed 2026-05-07 | $106.99M derived: sum of 2 quarters · filed 2026-05-07 | $151.89M derived: sum of 3 quarters · filed 2026-05-07 | $197.69M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $58.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $103.25M derived: sum of 2 quarters · filed 2026-02-26 | $149.05M derived: sum of 3 quarters · filed 2026-08-06 | $191.07M 10-K · filed 2026-02-26 |
| 2025-09-30 | $44.90M 10-Q · filed 2025-11-06 | $90.70M derived: sum of 2 quarters · filed 2026-08-06 | $132.72M 10-Q · filed 2025-11-06 | $178.44M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $45.80M 10-Q · filed 2026-08-06 | $87.82M 10-Q · filed 2026-08-06 | $133.53M derived: sum of 3 quarters · filed 2026-08-06 | $192.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $42.02M 10-Q · filed 2026-05-07 | $87.73M derived: sum of 2 quarters · filed 2026-05-07 | $146.20M derived: sum of 3 quarters · filed 2026-05-07 | $195.46M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $45.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $104.17M derived: sum of 2 quarters · filed 2026-02-26 | $153.44M derived: sum of 3 quarters · filed 2026-02-26 | $199.50M 10-K · filed 2026-02-26 |
| 2024-09-30 | $58.46M 10-Q · filed 2025-11-06 | $107.72M derived: sum of 2 quarters · filed 2025-11-06 | $153.79M 10-Q · filed 2025-11-06 | $211.17M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $49.26M 10-Q · filed 2025-08-07 | $95.33M 10-Q · filed 2025-08-07 | $152.71M derived: sum of 3 quarters · filed 2026-02-26 | $200.24M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $46.06M 10-Q · filed 2025-05-08 | $103.44M derived: sum of 2 quarters · filed 2026-02-26 | $150.98M derived: sum of 3 quarters · filed 2026-02-26 | $200.65M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $57.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $104.91M derived: sum of 2 quarters · filed 2026-02-26 | $154.59M derived: sum of 3 quarters · filed 2026-02-26 | $203.00M 10-K · filed 2026-02-26 |
| 2023-09-30 | $47.53M 10-Q · filed 2024-11-07 | $97.21M derived: sum of 2 quarters · filed 2024-11-07 | $145.62M 10-Q · filed 2024-11-07 | $201.28M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $49.68M 10-Q · filed 2024-08-01 | $98.09M 10-Q · filed 2024-08-01 | $153.75M derived: sum of 3 quarters · filed 2025-02-27 | $208.45M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $48.41M 10-Q · filed 2024-05-02 | $104.07M derived: sum of 2 quarters · filed 2025-02-27 | $158.78M derived: sum of 3 quarters · filed 2025-02-27 | $206.24M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $55.66M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $110.37M derived: sum of 2 quarters · filed 2025-02-27 | $157.83M derived: sum of 3 quarters · filed 2025-02-27 | $204.31M 10-K · filed 2025-02-27 |
| 2022-09-30 | $54.71M 10-Q · filed 2023-11-02 | $102.17M derived: sum of 2 quarters · filed 2023-11-02 | $148.65M 10-Q · filed 2023-11-02 | $197.18M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $47.46M 10-Q · filed 2023-08-03 | $93.94M 10-Q · filed 2023-08-03 | $142.47M derived: sum of 3 quarters · filed 2024-02-29 | $197.67M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $46.48M 10-Q · filed 2023-05-04 | $95.01M derived: sum of 2 quarters · filed 2024-02-29 | $150.21M derived: sum of 3 quarters · filed 2024-02-29 | $220.22M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $48.52M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $103.72M derived: sum of 2 quarters · filed 2024-02-29 | $173.74M derived: sum of 3 quarters · filed 2024-02-29 | $251.87M 10-K · filed 2024-02-29 |
| 2021-09-30 | $55.20M 10-Q · filed 2022-11-03 | $125.22M derived: sum of 2 quarters · filed 2022-11-03 | $203.34M 10-Q · filed 2022-11-03 | $266.94M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-06-30 | $70.02M 10-Q · filed 2022-08-04 | $148.14M 10-Q · filed 2022-08-04 | $211.75M derived: sum of 3 quarters · filed 2023-03-02 | $274.63M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-03-31 | $78.02M 10-Q · filed 2022-05-05 | $141.73M derived: sum of 2 quarters · filed 2023-03-02 | $204.61M derived: sum of 3 quarters · filed 2023-03-02 | |
| 2020-12-31 | $63.71M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $126.59M derived: sum of 2 quarters · filed 2023-03-02 | $255.51M 10-K · filed 2023-03-02 | |
| 2020-09-30 | $62.88M 10-Q · filed 2021-11-04 | $191.81M 10-Q · filed 2021-11-04 | ||
| 2019-12-31 | $311.31M 10-K · filed 2022-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |